Antitransgene Rejection Responses Contribute to Attenuated Persistence of Adoptively Transferred CD20/CD19-Specific Chimeric Antigen Receptor Redirected T Cells in Humans
Michael C. Jensen(Seattle Children's Hospital), Stephen J. Forman(City Of Hope National Medical Center), Julie R. Ostberg(CTI BioPharma (United Kingdom)), Laurence J.N. Cooper(The University of Texas MD Anderson Cancer Center), Leslie Popplewell(City Of Hope National Medical Center), Michael Kalos(Pillar College), David DiGiusto(Beckman Research Institute)
Cited by 522
Related Papers
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
|New England Journal of Medicine|2016|1.8k
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
|The Lancet Oncology|2014|1.3k
Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults
|Blood|2017|1.1k
Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma
|Clinical Cancer Research|2015|754